Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2625

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

Chemical structure of duloxetine hydrochloride showing the fused aromatic rings including a naphthalene moiety and a thiophene ring, with an oxygen atom and a methylated amine group bonded to the central carbon framework.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

Kaplan-Meier estimator chart showing the proportion of patients with relapse over time (days) comparing Duloxetine treatment to placebo. The x-axis represents time from randomization to relapse in days, and the y-axis indicates the proportion of patients experiencing relapse. The chart presents two curves: one for placebo and one for Duloxetine.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

A Kaplan-Meier estimator curve showing the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine treatment groups. The graph depicts relapse proportions increasing with time, with placebo showing a higher relapse rate compared to duloxetine over approximately 250 days.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and placebo. The graph illustrates varying trends of patient improvement with Duloxetine doses generally showing higher improvement compared to placebo.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo groups. The y-axis shows the percentage of patients improved from 0 to 100%, and the x-axis shows percent improvement in pain from baseline ranging from >0 to 100%.*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo. The y-axis represents the percentage of patients improved, and the x-axis represents percent improvement in pain from baseline, ranging from >0 to 100 percent. Duloxetine twice daily shows the highest patient improvement across the pain improvement range compared to once daily and placebo.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different data lines), and placebo. The graph illustrates how patient improvement varies with pain reduction for each treatment group.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares patients treated with Duloxetine 60 mg once daily versus placebo, plotting percent improvement in pain from baseline against percentage of patients improved. The Duloxetine line consistently shows higher improvement percentages across pain relief levels.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Duloxetine shows a higher percentage of patient improvement across most levels of pain improvement compared to placebo.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare Duloxetine 60 mg once daily with placebo, showing patient improvement rates across various pain improvement thresholds from 0% to 100%.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo to Duloxetine 60/120 mg once daily, showing a higher percentage of patient improvement with Duloxetine across increasing pain improvement thresholds.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

Duloxetine 60 mg delayed release capsules packaging label. The label includes the product name Duloxetine, strength 60 mg, dosage form delayed release capsules, and the labeler Bryant Ranch Prepack. The packaging also features a design with black and gray geometric shapes arranged symmetrically.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 60 mg delayed-release capsules are shown in a blister pack containing ten capsules. The capsules are two-toned with a white and darker maroon or brown color. Each capsule is imprinted with identifying numbers or letters visible on the darker half. The packaging is typical for a prescription oral capsule product.*

FDA Label Image

Label (Lbl713352625)

Label for Duloxetine Delayed-Release Capsules USP 60 mg by Bryant Ranch Prepack. The label indicates a package of 30 capsules, with the NDC 71335-2625-1. It includes storage instructions, a QR code for the package insert, and notes that the capsules contain 67.3 mg Duloxetine Hydrochloride USP equivalent to 60 mg Duloxetine. Manufactured by Lupin Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.